Crescent Biopharma, Inc. (CBIO) Stock: Price, Forecast & Analyst Target
Crescent Biopharma, Inc. (CBIO) — MoonshotScore 27/100 (Weak band), calculated Nov 22, 2026. Price $13.00 (+0.70%), as of the Nov 20, 2026 trading session; market cap $506M.
Educational signal · not a buy or sell recommendation · How to read this
Crescent Biopharma, Inc. · CBIO · NASDAQ
Crescent Biopharma, Inc. is a biotechnology company focused on researching and developing cancer therapy candidates. Their pipeline includes bispecific antibodies and strategic partnerships for oncology therapeutics.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Crescent Biopharma (CBIO)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strong balance sheet, but bottom-tier quality, stalling growth and an expensive valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Shrinking; Momentum: Quiet.
- quarterly revenue $11M (Q4 FY2025, quarter ended Dec 2025)
- EPS beat 0 of the last 4 reports
- Altman Z 10.00 · Piotroski F 4
Holding back: weak fundamentals, a rich price, soft growth
Helping: balance-sheet strength
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 26 | Weak | |
| 26 | Weak | |
| 26 | Weak | |
| 26 | Weak | |
| 26 | Weak | |
| 26 | Weak |
The score moved from 26 in the stored Nov 21, 2026 snapshot to 27 in the current publication computed Nov 22, 2026 (+1); the largest pillar moves were Momentum +3 and Valuation +1. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $13.00 |
| Change on the day | +0.70% |
| Market capitalisation | $506M |
| Price / earnings (trailing) | -5.97 |
| Shares traded on the day | 422.4K |
Price & events
Other perspectives
Council score for Crescent Biopharma (CBIO): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 22, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Englander-style lens and Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens disagrees with the Valuation pillar (Rich, 30 of 100): it reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 22, 2026, except a card that shows its own read date.
What is Crescent Biopharma (CBIO), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Crescent Biopharma, Inc. (CBIO) is listed on NASDAQ. It employs 80 people. In Q4 FY2025 it reported revenue of $11M and net income of -$92M. The market values it at $506M.
What do the latest results show for Crescent Biopharma (CBIO)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of $11M. Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 2 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | $11M | -$92M | -$4.58 (diluted) |
| Q1 FY2026 | $1M | -$23M | -$0.77 (diluted) |
What are the financial strengths and risks for Crescent Biopharma (CBIO)?
Short answer
The MoonshotScore pillars rate balance-sheet strength as strengths. What is holding it back is weak fundamentals, a rich price, soft growth. The distress and quality screens read Altman Z 10.00 · Piotroski F 4. Trailing ratios: current ratio 12.57.
What should you watch next at Crescent Biopharma (CBIO)?
Short answer · as of
Current published price targets run low $36.00 · high $36.00 · consensus $36.00 · median $36.00 against a quoted price of $13.00 (as of Nov 20, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q4 FY2025) was filed Feb 26, 2026 — 8 months ago.
Checked against the records this page reads, on the dates shown above.
How does Crescent Biopharma compare with its peers?
Short answer
Crescent Biopharma's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $18.41 Nov 20, 2026 | $1.31B | 96 5-pillar Nov 22, 2026 | |
| $13.09 Nov 20, 2026 | $462M | 92 5-pillar Nov 22, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 22, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 22, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 87 5-pillar Nov 22, 2026 | |
| $46.63 Nov 20, 2026 | $1.39B | 77 5-pillar Nov 22, 2026 | |
| $11.54 Nov 20, 2026 | $817M | 69 5-pillar Nov 22, 2026 | |
| $19.19 Nov 20, 2026 | $1.18B | 69 5-pillar Nov 22, 2026 | |
| $38.85 Nov 20, 2026 | $1.26B | 69 5-pillar Nov 22, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 22, 2026 | |
| $7.98 Nov 20, 2026 | $780M | 64 5-pillar Nov 22, 2026 | |
| $30.43 Nov 20, 2026 | $1.02B | 64 5-pillar Nov 22, 2026 | |
| Crescent Biopharma (CBIO) — this page | $13.00 | $506M | 27 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $36.00 – $36.00
- Consensus target
- $36.00
- Median target
- $36.00
Consensus record · Captured .
Measured against a quoted price of $13.00 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 18, 2026
- Transactions
- 23
- Identified insiders
- 12
- Purchases
- 2
- Sales
- 16
- Other transactions
- 5
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CBIO in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CBIO in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Crescent Biopharma (CBIO)?
Crescent Biopharma Stock: Key Questions Answered
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for CBIO?
CBIO carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Crescent Biopharma, Inc. is a biotechnology company focused on researching and developing cancer therapy candidates.
Is CBIO a good stock to buy?
Stock Expert AI does not rate CBIO buy, sell or hold. Crescent Biopharma, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CBIO stock price today?
The last price recorded for Crescent Biopharma, Inc. (CBIO), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CBIO price target?
The analyst consensus price target for Crescent Biopharma, Inc. (CBIO), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the key factors to evaluate for CBIO?
Crescent Biopharma, Inc. (CBIO) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. The company maintains a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., enhancing its development and commercialization capabilities in oncology. Not financial advice.
How frequently does CBIO data refresh on this page?
CBIO's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CBIO's recent stock price performance?
Crescent Biopharma, Inc. (CBIO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative bispecific antibody technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CBIO overvalued or undervalued right now?
Crescent Biopharma, Inc. (CBIO) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of CBIO?
Fractional-share availability for Crescent Biopharma, Inc. (CBIO) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 20 figures on this page — 16 from Financial Modeling Prep (FMP), 2 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com